Dark

Check out our Dark Pool Levels

IMMU
Immunomedics, Inc. Common Stock
stock NASDAQ

Inactive

Oct 22, 2020

87.86USD+0.046%(+0.04)15,318,630

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Oct 5, 2021

02:08PM EDT 2-23-10 Small Cap Market News and Stock Highlights from SmallCapVoice.com Benzinga

Nov 27, 2020

08:00AM EST The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases. GlobeNewswire Inc

Oct 23, 2020

09:28AM EDT Gilead Completes Transaction To Acquire Immunomedics - RTTNews

09:17AM EDT Gilead Sciences Completes $21B Acquisition Of Immunomedics, Inc. Benzinga

Oct 22, 2020

10:29AM EDT Stocks Trading Near 52-Week Highs Just After Open On Thursday, Oct. 22, 2020: MXL, LOACR, PRPH, QELLU, PBI, LOACW, ACAMW, LPL, HBM, ACAM, CSX, ALACW, ERIC, SNA, AMTX, BCOV, EVK, ALGN, TC, PAG, CRSR, WHR, SQBG, STNE, IMMU, REPL, BOTZ, ATSG, SFIX, SID Benzinga

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

09:39AM EDT Stocks Trading Near 52-Week Highs In The Pre-Market Session On Wednesday, Oct. 21, 2020: AN, PSTH, CALX, MRIN, SOAC, GLBS, SCCO, TWTR, PINS, JKS, SNAP, ERIC, CSIQ, IMMU, STAA, SSTK, UPS, PHR, GWACU, AVTR, SRACW, PANA, JCTCF, PAYC, CRSR, SOCL, SMMC, Benzinga

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

05:42AM EDT ProteoNic Announced Licensing of Technology for Production of Biologics to Immunomedics; Financial Details Not Disclosed Benzinga

Oct 12, 2020

08:09AM EDT Immunomedics Announces FDA Orphan Drug Designation Of Trodelvy For Adult And Pediatric Glioblastoma RTTNews

08:00AM EDT Immunomedics, Inc.(NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the treatment of adult and pediatric patients with glioblastoma. GlobeNewswire Inc

Oct 8, 2020

11:47AM EDT Immunomedics Shares Quiet Following FDA AccessData.gov Alert For Orphan Drug Designation For Its Malignant Glioma Treatment Benzinga

Oct 5, 2020

11:03PM EDT Shareholders are Encouraged to Contact the Firm - CBMG, VRTU, MR, IMMU, JCAP PR Newswire

Oct 2, 2020

08:55PM EDT WeissLaw LLP Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing PR Newswire

Oct 1, 2020

11:35AM EDT Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: GlobeNewswire Inc

Sep 25, 2020

10:55PM EDT WeissLaw LLP Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing PR Newswire

10:35PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About PR Newswire

Sep 23, 2020

02:09PM EDT Gilead To Sell $7.25B Of Bonds To Fund Immunomedics Deal Benzinga

Sep 22, 2020

03:00PM EDT SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of GlobeNewswire Inc

Sep 20, 2020

09:46PM EDT (IMMU) Alert: Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88 PR Newswire

08:48AM EDT Immunomedics Announced Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy in Metastatic Urothelial Cancer at ESMO 2020 Benzinga

Sep 19, 2020

11:00AM EDT Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) GlobeNewswire Inc

10:35AM EDT Immunomedics Says Trodelvy Extends Survival In Phase 3 ASCENT Study Of Metastatic Triple-Negative Breast Cancer RTTNews

10:30AM EDT Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival(OS) of 12.1 months compared to6.7 months for standard single-agent chemotherapy GlobeNewswire Inc

Sep 18, 2020

08:27AM EDT Immunomedics Inc. (IMMU) said Friday that early-stage clinical results with Trodelvy in brain cancers were encouraging. The results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM). RTTNews

08:06AM EDT Immunomedics: Early Intracranial Responses Are Encouraging In Sacituzumab Govitecan In CNS Tumors RTTNews

08:02AM EDT Immunomedics Reports Trodelvy Delivered Improvements In Inhibitory Concentration Of SN-38 For BMBC, rGBM In Brain Cancer Patients Benzinga

08:00AM EDT Immunomedics, Inc.(NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38 for BMBC and rGBM, respectively, and produced partial responses in both cohorts of brain cancer patients. GlobeNewswire Inc

Sep 16, 2020

01:29PM EDT Lifshitz Law Firm, P.C. Announces Investigation of Immunomedics, GlobeNewswire Inc

Sep 15, 2020

01:52PM EDT Moore Kuehn Encourages IMMU, ONDK, VRTU, and OTEL Investors to Contact Law Firm PR Newswire

01:33PM EDT ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders PR Newswire

08:19AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:08AM EDT Jefferies Downgrades Immunomedics to Hold, Raises Price Target to $88 Benzinga

Sep 14, 2020

06:58PM EDT SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc. PR Newswire

02:57PM EDT IMMUNOMEDICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Immunomedics - IMMU Business Wire

02:33PM EDT Mid-Afternoon Market Update: Dow Rises 350 Points; Cassava Sciences Shares Spike Higher Benzinga

01:59PM EDT SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation GlobeNewswire Inc

12:47PM EDT Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology' Benzinga

12:07PM EDT Mid-Day Market Update: Immunomedics Jumps Following Acquisition News; Mallinckrodt Shares Slide Benzinga

10:33AM EDT Benzinga's Top Upgrades, Downgrades For September 14, 2020 Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Open Higher; Nvidia Reports $40B Deal To Buy SoftBank's Arm Holdings Benzinga

09:59AM EDT Shares of clinical-stage biopharmaceutical company Immunomedics, Inc. (IMMU) are surging more than 100% Monday morning on news of Gilead Sciences' agreement to buy Immunomedics for $88.00 per share, cash. RTTNews

08:16AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:43AM EDT Wells Fargo Downgrades Immunomedics to Equal-Weight Benzinga

06:25AM EDT HC Wainwright & Co. Downgrades Immunomedics to Neutral, Raises Price Target to $88 Benzinga

05:55AM EDT A Peek Into The Markets: US Stock Futures Surge; Nvidia To Acquire SoftBank Chipmaker Arm Benzinga

05:25AM EDT Immunomedics Shares Rise 106% Premarket After Gilead Agrees to Buy the Biopharmaceutical Company for $88/Share in Cash Benzinga

01:27AM EDT Gilead To Explore Trodelvy Drug Against Different Cancers After $21B Merger With Immunomedics Benzinga

Sep 13, 2020

10:00PM EDT Immunomedics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Immunomedics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - IMMU Business Wire

09:17PM EDT Gilead Sciences Inc. (GILD) agreed to buy Immunomedics (IMMU) for $88.00 per share in cash, valuing the company at about $21 billion, the two companies said in a statement on Sunday. RTTNews

03:21PM EDT Gilead Sciences to Acquire Immunomedics for $88/Share in Cash Benzinga

03:00PM EDT Gilead Sciences to Acquire Immunomedics Business Wire

Sep 12, 2020

06:22PM EDT Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal Benzinga

Sep 9, 2020

07:00AM EDT Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy in brain tumors GlobeNewswire Inc

Sep 2, 2020

08:00AM EDT Immunomedics, Inc.(NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences: GlobeNewswire Inc

Aug 20, 2020

07:21PM EDT Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel PR Newswire

Aug 17, 2020

08:14AM EDT Immunomedics Reports FDA Approval Of Samsung Biologics As Antibody Manufacturer For Trodelvy RTTNews

08:07AM EDT Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy Benzinga

08:00AM EDT Immunomedics Announces FDA Approval of Samsung Biologics as GlobeNewswire Inc

Aug 10, 2020

09:16AM EDT Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to $40 Benzinga

Aug 6, 2020

01:43PM EDT Piper Sandler Maintains Overweight on Immunomedics, Raises Price Target to $60 Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 5, 2020

04:01PM EDT Immunomedics Q4 EPS $(0.73) Misses $(0.35) Estimate, Sales $20.07M Beat $12.91M Estimate Benzinga

04:00PM EDT Encouraging early adoption of Trodelvy in U.S. with $20.1M net sales in first two months of launch GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Aug 3, 2020

12:46PM EDT B of A Securities Maintains Buy on Immunomedics, Raises Price Target to $47 Benzinga

Jul 27, 2020

02:23PM EDT Immunomedics Analyst Says Trodelvy Likely To Capture 50% Market Share Benzinga

08:25AM EDT Jefferies Maintains Buy on Immunomedics, Raises Price Target to $55 Benzinga

08:00AM EDT Immunomedics, Inc.(NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2020 and provide a corporate update. GlobeNewswire Inc

Jul 13, 2020

04:01PM EDT Immunomedics Expands Collaboration With Roche Evaluating Trodelvy In Combination With Tecentriq Into Urothelial And Non-Small Cell Lung Cancers Benzinga

04:00PM EDT Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer GlobeNewswire Inc

Share